Iron chelation afforded cardioprotection against H2O2-induced H9C2 cell injury: Application of novel 3-hydroxy pyridine-4-one derivatives

Abstract

The concept of iron-driven oxidative events remains the principal mechanism of cardiotoxicity. Iron-induced cardiotoxicity serves as the main cause of heart failure in transfusion-dependent disorders and anthracycline-induced cardiotoxicity [1,2]. These disorders are formidable in many patients by intensive iron chelating therapies [3]. Therefore, design and development of novel iron chelator candidates are attractive research topics in this area. For three decades, L1 has been the only orally active iron chelator.